AMO Pharma

Executive Summary

AMO Pharma is a London-based private biopharmaceutical company focused on developing treatments for rare genetic disorders, with a lead asset, Tideglusib, a GSK-3 inhibitor. The company's pipeline targets congenital myotonic dystrophy (CDM) and arrhythmogenic cardiomyopathy (ACM), addressing significant unmet needs. Tideglusib has demonstrated safety and efficacy signals in earlier trials, and AMO is advancing it through a registrational Phase 2/3 trial in CDM (NCT05004129) and a Phase 2 trial in ACM (NCT06174220). Despite being privately held with limited financial disclosure, AMO Pharma's focus on validated biology and rare disease pathways positions it as a potential value driver in the neuromuscular and cardiovascular rare disease space. The company's progress will hinge on upcoming clinical data readouts.

Upcoming Catalysts (preview)

• Q4 2026Topline data from Phase 2/3 trial of Tideglusib in Congenital Myotonic Dystrophy (NCT05004129)60% success
• Q2 2027Interim or final data from Phase 2 trial of Tideglusib in Arrhythmogenic Cardiomyopathy (NCT06174220)50% success